Health Phase 3 Trial Reveals Anifrolumab’s Efficacy for Lupus Patients A recent phase 3 trial has confirmed that subcutaneous anifrolumab (branded as Saphnelo) offers significant treatment benefits for patients suffering from systemic lupus erythematosus... Editorial10 January, 2026